Differential effects of metformin and pioglithazone on hs-CRP in patients with type II DM.

Not Applicable

• Conditions: diabetes mellitus II.; non-insulin-dependent diabetes mellitus

• Registration Number: IRCT201109067482N1
• Lead Sponsor: Qazvin University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Diabetic patients (type 2) receiving diet or monotherapy by sulphonylurea, HbA1C=7.5 and FBS=140
Exclusion criteria: known case of inflammatory disease such as IBD, RA, vascultis, recent infection in one month suffering from malignancy, receiving other drug that decrease CRP level .[COX inhibitor (ASA, Celecoxib ), platlete aggregation inhibitor (clopidogrel, abciximab ), lipid lowering agents (Statins, Ezetimibe, Fenofibrate, Niacin, B blockers, antioxidants (vit E), ACEIs, ARBs ,CCBs except Amlodipine, Tamoxifen], Soye isoflavon enriched food; consumption of oral estrogen that increase CRP level, hypersensitivity to Metformin or Pioglitazone, Insulin use, Corticosteroid use, Cr >1.4 mg/dl, severe abnormal liver function test, pregnancy

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
HsCRP. Timepoint: before study and 3 months after treatment. Method of measurement: Kit for CRP_ Latex Inhanced Immunoturbidimetric Assay A Quantitative Test for C-Reactive Protein Determination by Parsazmun company (unitage: mg/L).

Secondary Outcome Measures

Name	Time	Method
HbA1C. Timepoint: before study and 3 months after treatment. Method of measurement: Kit for HbA1C in whole blood with Immunoturbidimetric Assay, a Quantitative Test by Parsazmun Company (unitage: % ).